Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · IEX Real-Time Price · USD
15.91
+0.17 (1.08%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Zai Lab Employees
Zai Lab had 2,175 employees on December 31, 2023. The number of employees increased by 139 or 6.83% compared to the previous year.
Employees
2,175
Change (1Y)
139
Growth (1Y)
6.83%
Revenue / Employee
$122,629
Profits / Employee
-$153,848
Market Cap
1.57B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,175 | 139 | 6.83% |
Dec 31, 2022 | 2,036 | 85 | 4.36% |
Dec 31, 2021 | 1,951 | 757 | 63.40% |
Dec 31, 2020 | 1,194 | 502 | 72.54% |
Dec 31, 2019 | 692 | 383 | 123.95% |
Dec 31, 2018 | 309 | 221 | 251.14% |
Dec 31, 2017 | 88 | 36 | 69.23% |
Dec 31, 2016 | 52 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Addus HomeCare | 34,846 |
U.S. Physical Therapy | 6,720 |
Warby Parker | 3,491 |
UFP Technologies | 3,093 |
Myriad Genetics | 2,700 |
Taro Pharmaceutical Industries | 1,554 |
ADMA Biologics | 624 |
Inhibrx | 172 |
ZLAB News
- 12 days ago - Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024 - Business Wire
- 16 days ago - Zai Lab Statement on Executive Management Team's Agreement on Share Activities - Business Wire
- 25 days ago - Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs - Business Wire
- 26 days ago - Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic - Business Wire
- 4 weeks ago - Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer - Business Wire
- 6 weeks ago - Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors - Business Wire
- 7 weeks ago - Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) - Business Wire
- 7 weeks ago - Zai Lab Announces Participation in March Investor Conference - Business Wire